Diversity in Oncology fosters courageous conversations about strategies for the delivery of equitable high quality cancer care for all including clinical trials, so that this cross-stakeholder, cross-cultural initiative can take action to make the clinical trial enterprise more inclusive and responsive to populations that are currently underrepresented.
Why This Initiative is Needed Now
Hear from Hong Tang, Co-Lead of PAN Asian Network, Health Equity Initiative at BMS, on when the idea for Diversity in Oncology was born. Listen to discover the purpose of this initiative which aims to uncover the barriers to clinical trial access by bringing together voices of patients, physicians, and researchers of diverse populations to work towards structural improvements and solutions.
Who Should Attend
- Local and national community organizations that focus on health equity
- Patients and caregivers
- Healthcare providers
- Clinical trial teams and principal investigators
- Schools of public health
- Anyone interested in discussing health equity in clinical trials
Amplifying Lived Experiences and Meaningful Collaborations To Improve Health Outcomes
A Diversity in Oncology Initiative in Boston
Diversity in Oncology is a first of its kind initiative to learn from and co-create solutions to address health inequities with three specific communities: the AAPI, Black/African American, Hispanic/Latin. Bristol Myers Squibb in partnership with Gryt Health have been listening to the local leaders in these three communities to learn the barriers to accessing quality healthcare. Delving into real world examples, we will hear from community health leaders in Boston, MA on how complex and unique obstacles to care affect their communities. Leave this session with a better understanding of language, stigma and screening challenges to be able to take active roles in creating more inclusive and responsive experience for underserved humans.